Market access webinar

Positioning for market access success in the evolving landscape of precision medicine

Whatever your preferred terminology  precision/stratified/ personalized medicine, pharmacogenomics, or something else – there are an increasing number of targeted therapies that can be effective in a range of  different diseases. To date, only a few of these are indicated independent of histology or tumor location.

Fill in your details to watch this webinar

It is important for manufacturers to explore the advantages and challenges of different positioning strategies through a market access lens.

Join us, as we anticipate the future market access pathways for tumor agnostic/histology independent medicines. 

Discussion points: 

  • Discover why the number of tumor agnostic/histology products remains limited. 
  • Examine the challenges and solutions for reimbursement and patient access to precision medicine products.   
  • Explore the learnings for access from recently launched precision medicine products. 

Key learning objectives: 

  • Hear the latest on the direction of travel for precision medicine. 
  • Understand evidence requirements and learn about approaches to establishing comparative benefit for tumor agnostic/ histology independent therapies. 
  • Find effective new ways to explain access challenges to stakeholders or colleagues in commercial, medical, and regulatory teams.  
  • Learn about real-world evidence initiatives to support better understanding of molecularly defined tumor types. 
  • Explore considerations and recommendations that can be applied to your assets in development.  

This webinar is essential viewing for all those in global and regional market access and HEOR roles who want to understand how the definition of disease is shifting to the molecular level and anticipate what this means for evidence generation requirements and value demonstration.

Presenters:

Clare has more than 25 years’ experience in precision medicine through R&D and commercial roles. Over the last 13+ years Clare has focused on market access for drugs and companion diagnostics leading and advising on a wide range of strategic and tactical projects at PRMA Consulting, part of Fishawack Health. 

Merel has more than 10 years’ consultancy experience and has worked on numerous projects in oncology and rare diseases, focusing on value communication, and has been the project lead on multiple PRMA Healthcheck® projects delivering market access and evidence generation strategies.

Devan has a broad experience in the management and delivery of RWE, HEOR, and market access and value engagement projects. During her time at PRMA Consulting, Devan has developed an extensive knowledge of market access for companion diagnostics and associated drugs.

Duration: 20 minutes.

Broadcast: 2023

Positioning for market access success in the evolving landscape of precision medicine

Previous webinars

Driving BioPharma Access in Europe: Insights for Markets Outside of EU5  

Read more >

Navigating the cell and gene therapy market access landscape

Read more >

Understanding the concept of early scientific advice and its purpose across HTA markets

Read more >

Increase your influence in early pipeline planning: why earlier value assessment of your assets through a payer lens makes a difference.

Read more >

How to demonstrate the value of vaccines in line with global NITAG and HTA requirements

Read more >

Market access for biotechnology

Read more >

How to build an optimized GVD to populate local HTA/payer templates

Read more >

Recommendations for driving your journey to digital excellence

Read more >

The PRMA Healthcheck®: the future of market access in Asia-Pacific

Read more >

PRMA Healthcheck® for assets in early stages of clinical development

Read more >

The evolution of the PRMA Healthcheck® for US payer archetypes

Read more >

Navigating the updated 2020 ICER value assessment framework

Read more >

Accelerate the time to patient access with the PRMA Navigator®

Read more >

EUnetHTA joint clinical assessments: where have we come from and where are we going?

Read more >

Future proofing for the 2020s market access trends

Read more >

Managed entry agreements: lessons from EU5

Read more >

CAR-T therapy: the future begins to take shape

Read more >

Indication-specific pricing: the obvious solution

Read more >

Payer perspectives on cell and gene therapies: opportunities and challenges

Read more >

Market access considerations for CAR-Ts: insights from ASH

Read more >

Patient-centricity: shaping value generation for HTA and market access

Read more >

Market access for PD-1 inhibitors: where are we now?

Read more >

Does 1+1 always equal 2? Valuing combinations

Read more >

Clarity or confusion: the role of value frameworks in oncology

Read more >